The activity of JAK/STAT and NF-κB in patients with rheumatoid arthritis

Advances in Clinical and Experimental Medicine

Volumn 25, Issue 4, 2016, Pages 709-717

  Świerkot, Jerzy ^a   Nowak, Beata ^a   Czarny, Anna ^b   Zaczyńska, Ewa ^b   Sokolik, Renata ^a   Madej, Marta ^a   Korman, Lucyna ^a   Sebastian, Agata ^c   Wojtala, Patryk ^c   Lubiński, Łukasz ^c   Wiland, Piotr ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c UNIVERSITY OF WROC AW   (Poland)

Author keywords

NF B expression; Rheumatoid arthritis; STAT expression

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; LEUKOCYTE; MALE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIOCYTE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; JANUS KINASES; MALE; MIDDLE AGED; NF-KAPPA B; STAT TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84987600978     PISSN: 18995276     EISSN: 24512680     Source Type: Journal    
DOI: 10.17219/acem/61034     Document Type: Article

References (26)

1. Totoson P, Maguin-Gaté K, Prati C, Demougeot C: Mechanisms of endothelial dysfunction in rheumatoid arthritis: lessons from animal studies. Arthritis Res Ther 2014, 16, 202.
2. Ivashkiv LB, Hu X: The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective? Arthritis Rheum 2003, 48, 2092-2096.
3. Stark GR, Darnell JE: The JAK-STAT pathway at twenty. Immunity 2012, 36, 503-514.
4. Isomäki P, Junttila I, Vidqvist KL, Korpela M, Silvennoinen O: The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin-6 levels. Rheumatology 2015, 54, 1103-1113.
5. Mori T, Miyamoto T, Yoshida H, Asakawa M, Kawasumi M, Kobayashi T, Morioka H, Chiba K, Toyama Y, Yoshimura A: IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 2011, 23, 701-712.
6. Ortiz MA, Diaz-Torné C, Hernández MV, Reina D, de la Fuente D, Castellví I, Moya P, Ruiz JM, Corominas H, Zamora C, Cantó E, Sanmartí R, Juarez C, Vidal S: IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients. Clin Immunol 2015, 158, 174-182.
7. Verma IM: Nuclear factor (NF)-kB proteins: therapeutic targets. Ann Rheum Dis 2004, 63, Suppl 2, 57-61.
8. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD: Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 2006, 65, 1558-1564.
9. Malemud CJ: Intracellular Signaling Pathways in Rheumatoid Arthritis. J Clin Cell Immunol 2013, 19, 160.
10. Aparicio-Siegmund S, Sommer J, Monhasery N, Schwanbeck R, Keil E, Finkenstädt D, Pfeffer K, Rose-John S, Scheller J, Garbers C: Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget 2014, 30, 2131-2148.
11. Kraan TV, Gaalen F, Kasperkovitz P, Verbeet NL, Smeets TJ, Kraan MC, Fero M, Tak PP, Huizinga TW, Pieterman E, Breedveld FC, Alizadeh AA, Verweij CL: Rheumatoid arthritis is a heterogeneous disease. Evidence for differences in the activation of the STAT-1 pathway between tissues. Arthritis Rheum 2003, 48, 2132-2145.
12. Kasperkovitz PV, Verbeet NL, Smeets TJ, van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, Tak PP, Verweij CL: Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 2004, 63, 233-239.
13. Madej M, Sokalska-Jurkiewicz M, Nowak B, Czarny A, Zaczynska E, Wiland P: The activity of STAT3 in patients with rheumatoid arthritis. Adv Clin Exp Med 2008, 4, 405-409.
14. Krause A, Scaletta N, Ji JD, Ivashkiv LB: Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol 2002, 169, 6610-6616.
15. Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr WG, Takeda K, Akira S, Schoenberger SP, Yu H, Jove R, Sotomayor EM: A critical role for Stat3 signaling in immune tolerance. Immunity 2003, 19, 425-436.
16. Karonitsch T, Dalwigk K, Steiner C, Blüml S, Steiner G, Kiener HP, Smolen JS, Aringer M: Interferon signals and monocytic sensitization of the interferon signaling pathway in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 2012, 64, 400-408.
17. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD: Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66, 992-999.
18. Tong G, Zhang X, Tong W, Liu Y: Association between polymorphism in STAT4 gene and risk of rheumatoid arthritis: a meta-analysis. Hum Immunol 2013, 74, 586-592.
19. Liang Y, Pan H, Ye D: Therapeutic potential of STAT4 in autoimmunity. Expert Opin Ther Targets 2014, 18, 945-960.
20. Jones GW, Greenhill CJ, Williams JO: Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling is independent of IL-17A. Ann Rheum Dis 2013, 72, 1738-1742.
21. Aerts NE, Ebo DG, Bridts CH, Stevens WJ, De Clerck LS: T cell signal transducer and activator of transcription (STAT) 4 and 6 are affected by adalimumab therapy in rheumatoid arthritis. Clin Exp Rheumatol 2010, 28, 208-214.
22. Bhattacharyya S, Zhao Y, Kay T, Muglia L: Glucocorticoids target suppressor of cytokine signaling 1 (SOCS1) and type 1 interferons to regulate Toll-like receptor-induced STAT1 activation. PNAS 2011, 108, 9554-9559.
23. Strickland I, Ghosh S: Use of cell permeable NBD peptides for suppression of inflammation. Ann Rheum Dis 2006, 65, Suppl 3, 75-82.
24. Migita K, Izumi Y, Torigoshi T, Satomura K, Izumi M, Nishino Y, Jiuchi Y, Nakamura M, Kozuru H, Nonaka F, Eguchi K, Kawakami A, Motokawa S: Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway inrheumatoid synovial fibroblasts using small molecule compounds. Clin Exp Immunol 2013, 174, 356-363.
25. Scott LJ: Tofacitinib: A review of its use in adult patients with rheumatoid arthritis. Drugs 2013, 73, 857-874.
26. Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS: The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015, 74, 1311-1316.